SCHEDULE 13G: Prosight Entities Disclose 5.2% Passive Stake in Mural Oncology plc
Beneficial Ownership Disclosure
Prosight Management, LP and affiliated entities, including W. Lawrence Hawkins, have disclosed a passive beneficial ownership of 5.2% in Mural Oncology plc, totaling 900,000 ordinary shares.
Summary
- Prosight Management, LP, Prosight Partners, LLC, and W. Lawrence Hawkins each reported beneficial ownership of 900,000 ordinary shares of Mural Oncology plc, representing 5.2% of the outstanding class.
- Prosight Fund, LP reported beneficial ownership of 51,390 ordinary shares, representing 0.3% of the class.
- Prosight Plus Fund, LP reported beneficial ownership of 196,625 ordinary shares, representing 1.1% of the class.
- The reported percentages are based on 17,268,881 ordinary shares of Mural Oncology plc outstanding as of May 1, 2025, as disclosed in the Issuer's quarterly report on Form 10-Q filed on May 14, 2025.
- The filing is a Schedule 13G, indicating a passive investment not intended to change or influence control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.
Sentiment
Score: 5
Explanation: Neutral, as this is a standard disclosure of beneficial ownership by an institutional investor, not indicating positive or negative operational news for the company.
Future Outlook
NA
Industry Context
This filing reflects an institutional investor's passive stake in a publicly traded oncology company, a common occurrence in the investment landscape where funds build positions in specific sectors.
Stakeholder Impact
- Shareholders: Disclosure of a significant institutional stake (5.2%) by Prosight Management and affiliates may signal increased institutional interest or confidence in Mural Oncology plc, potentially influencing investor sentiment.
Key Dates
| Date | Description |
|---|---|
| 2025-05-01 | Date as of which 17,268,881 Ordinary Shares of Mural Oncology plc were outstanding, as disclosed in the Issuer's Form 10-Q. |
| 2025-05-14 | Date Mural Oncology plc's quarterly report on Form 10-Q for the period ended March 31, 2025, was filed with the SEC. |
| 2025-06-23 | Date of event which requires the filing of this Schedule 13G statement. |
| 2025-06-26 | Date the Schedule 13G statement and Joint Filing Agreement were signed. |
Keywords
Mural Oncology plc, Prosight Management LP, W. Lawrence Hawkins, Schedule 13G, Beneficial Ownership, Ordinary Shares, Institutional Investor, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.